★ WIDE MOAT STOCKS COMPARISON ★

Checking

Stock Comparison

AbbVie Inc. vs Johnson & Johnson

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$468.2B
Gross margin (TTM)71.5%
Operating margin (TTM)29.3%
Net margin (TTM)9.8%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-08-23
Moat score
50/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

Johnson & Johnson

JNJ · New York Stock Exchange

Market cap (USD)$651.3B
Gross margin (TTM)70.5%
Operating margin (TTM)26.8%
Net margin (TTM)21.5%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-08-23
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Johnson & Johnson's moat claims, evidence, and risks.

View JNJ analysis

Comparison highlights

  • Moat score gap: Johnson & Johnson leads (73 / 100 vs 50 / 100 for AbbVie Inc.).
  • Segment focus: AbbVie Inc. has 6 segments (48.9% in Immunology); Johnson & Johnson has 2 segments (64.7% in Innovative Medicine).
  • Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
  • Moat breadth: AbbVie Inc. has 2 moat types across 2 domains; Johnson & Johnson has 3 across 2.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

48.9%

Johnson & Johnson

Innovative Medicine

Market

Branded prescription pharmaceuticals (biopharma)

Geography

Global

Customer

Wholesalers, hospitals, retailers, healthcare professionals, payers

Role

Drug discovery, development, manufacturing, commercialization

Revenue share

64.7%

Side-by-side metrics

AbbVie Inc.
Johnson & Johnson
Ticker / Exchange
ABBV - New York Stock Exchange
JNJ - New York Stock Exchange
Market cap (USD)
$468.2B
$651.3B
Gross margin (TTM)
71.5%
70.5%
Operating margin (TTM)
29.3%
26.8%
Net margin (TTM)
9.8%
21.5%
Sector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
HQ country
US
US
Primary segment
Immunology
Innovative Medicine
Market structure
Oligopoly
Competitive
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
50 / 100
73 / 100
Moat domains
Legal, Demand
Legal, Demand
Last update
2026-08-23
2026-08-23

Moat coverage

Shared moat types

IP Choke PointBrand Trust

AbbVie Inc. strengths

No unique moat types yet.

Johnson & Johnson strengths

Training Org Change Costs

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

48.9%

Oncology

Competitive

10.9%

Neuroscience

Competitive

17.5%

Aesthetics

Oligopoly

7.9%

Eye Care

Competitive

3.4%

Other Key Products

Competitive

11.4%

Johnson & Johnson segments

Full profile >

Innovative Medicine

Competitive

64.7%

MedTech

Oligopoly

35.3%

Act on this comparison

Turn a two-stock debate into a systemSee the systematic rankings that surface stocks like ABBV and JNJ, with backtests and current holdings.

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.